Pre-Empting World AIDS Day Radio Weekend

Join Liam Scheff, Robert Scott Bell, and a panel of guest researchers, journalists and scientists on a full-frontal exposure of the AIDS machine.


Saturday 6PM – “The Investigation with Liam Scheff” with special guest, journalist Terry Michael, to discuss the ‘old-is-new’ pre-HIV drug ‘therapy’ for healthy gay and bisexual men. The death dealers at the NIH want to pre-drug you for AIDS, with drugs that will kill you over time, and can do so quickly! What is their rationale? And where is their shame? CLICK to listen “Does Poison Make You Healthy?”
Click to Download

Sunday – Two Full Hours on the Robert Scott Bell Show: – 1PM to 3PM EST, 10AM to Noon Pacific Time.

Call in at 1-800-259-5791 during show hours with your questions or comments. [CLICK]

Confirmed guests thus far include attorney David Steele, Investigator Clark Baker, Journalist Liam Scheff, Professor Charles Geshekter and Journalist Joan Shenton.

Sunday 6PM – “The Investigation” returns, with special guest, Jonathan Campbell, as we go through the history and technology of Linus Pauling, Matthias Rath, Vitamin C and reversing heart disease and immune deficiency (AIDS). [CLICK to listen – Vitamin C, Cancer and AIDS – What the NIH Doesn’t Want You To Hear]

Tune in and learn about the AIDS monster….

The news from on repeats like a nervous tick: “New drug breakthroughs could save the world from AIDS! This could be the one! The long sought Holy Grail.”

And every year, we’re sold a new cure – a potential breakthrough!  But it’s always been the same news for Twenty-FIVE SOLID YEARS!  “Look! We’re almost there! Just send MORE MONEY!!!”

So, is it true? Is the new breakthrough new?  Before we can answer the question, we must define our terms:

  • What is AIDS? It is Multifactorial; it is poverty and drug abuse – illnesses that are real! But under the “AIDS” banner, they are given a new label, a one-size-fits all brand name diagnosis.
  • What is HIV? “It” was LAV, then HTLV-3, then HIV, and now? It’s the “Trojan Exosome!”

“It” is a misnomer – another brand name for thousands of changeable bits of DNA, sucked out of cell cultures, passed through chemical stimulation to produce bits of protein. The AIDS mainstream makes a religious item out of these proteins, and grinds them down to synthetic ‘consensus agreed’ molecules, grown in labs. They say they represent one unique particle, even though they’ve been gathered from the four winds! And these proteins occur in people both sick and healthy.

AIDS is a brand name by which powerful pharma companies and governments convince you that the endemic and brutalizing poverty suffered by a majority of the world is somehow sexually contagious, and must be treated by toxic drugs and condoms – population control mechanisms….

On this weekend’s shows, we hammer and shake the paradigm and see what comes loose, and watch it tumble down, only to be put up again by your tax dollars, spent and misspent by Anthony Fauci’s N.I.H.

When will you take objection to the fraud? What if you were given a fraudulent HIV test diagnosis? Would you think, read and fight? Or would you lay down and take the drugs they prescribed to you?

Tune in to learn about this deadly paradigm, and how it has infected all of medical science….



  1. Study Oversight
    The study was designed by four of the investigators in collaboration with all the site investigators and communities. DAIDS reviewers approved the protocol, which was developed by the study investigators, and monitored the conduct of the trial at study sites. The Bill and Melinda Gates Foundation also provided funding but did not have a role in protocol development or site monitoring. Gilead Sciences donated both FTC–TDF and placebo tablets and provided travel-related support for meetings conducted by non-Gilead investigators.


    HIV-positive patients may offer gay and bisexual men some protection against contracting the virus, the authors of a new study say.

    Trials of the combination drug Truvada among nearly 2,500 men suggested it could reduce the chances of male-to-male HIV infection by 44%.

    Those using the drug regularly could further reduce the risk of infection, it was claimed.

    The study is published in the New England Journal of Medicine.

    Pills and condoms

    Truvada is the trade name of a drug manufactured by the California-based company Gilead Sciences Inc which combines two antiretroviral drugs, used to treat Aids.

    But this new study looks at whether it could be used to prevent HIV infection in the first place.

    “We need to know if we get similar results in women as well as in heterosexual men, which we have reason to believe we will” – Quote Dr Anthony Fauci Director, National Institute of Allergy and Infectious Diseases

    Almost 2,500 gay or bisexual men were randomly selected in Peru, Ecuador, Brazil, South Africa, Thailand and the United States. Half were given the pill, half were given dummy tablets.

    All the men were also given condoms and counseling on safe sex.

    What the researchers found after about a year of testing was that the drug appeared to cut male-to-male HIV transmission by 44%, when the group taking the pill was compared with the placebo group.

    Those who took the pill regularly were deemed to have reduced their risk of infection further, by up to 73%, and blood tests were run to confirm this relationship between pill-usage and protection levels.

    The research was funded by the Bill & Melinda Gates Foundation, and the federal US body, the National Institute of Allergy and Infectious Diseases (NIAID). The pills were donated by their manufacturer.

    NIAID director, Dr Anthony Fauci, conceded more work needed to be done, but called the results impressive.

    “This has been done in men who have sex with men. We need to know if we get similar results in women as well as in heterosexual men, which we have reason to believe we will,” he told the BBC.

    “We also need to get a long term view of were there any toxicities. We didn’t see anything that was significant but we need to follow that for a long period of time.”
    Questions and concerns

    The trial does of course raise questions and concerns. Is it possible, for instance, that the results were skewed by greater condom use in the group that took the pill; and won’t such findings encourage some men to dispense with condoms altogether in favour of a drug?

    There is also the issue of prohibitive cost of Truvada, which retails in the US for around $36 a day, and which makes the drug unaffordable to many possible users.

    Dr Fauci argues that the two groups were fully randomised and says that drugs can only play a complementary role in the war on HIV. Condoms and fewer partners, he said, remain the first line of defence.

    “We’re hoping that if this does become a useable tool in prevention, then the associated counseling will complement the effect of the drug and stop people becoming cavalier about it and say ‘now I have a pill I don’t have to worry’.

    “That’s exactly the opposite of what we want to happen. We want to add something rather than have it replace something.”

    Sir Nick Partridge, chief executive of the Terrence Higgins Trust, called the trial results “potentially significant”.

    “It’s vital that we expand the ways we can prevent HIV transmission, particularly amongst those most at risk,” he said in a statement. “This trial proves that HIV treatment will have an impact on prevention, but that it’s not ready for widespread use yet.

    “Three major hurdles are still going to be its cost, the risks of drug-resistant strains of HIV developing and taking a drug treatment every day.”

  3. From “Does the New York Times Want to Kill Gay Men?” by Liam Scheff GNN 2006

    Where, one might ask, does an inspired idea like this come from? The answer: the streets of San Francisco. And I mean, the streets. The trial in that fair city, with 400 healthy, HIV-negative, gay and bisexual men, is being conducted Dr. Susan Buchbinder, head of HIV research at the San Francisco Department of Public Health.

    The Times reported that Buchbinder decided to conduct the Tenofovir trials for two reasons. The first: “because Tenofovir PrEP had worked well in research monkeys.” The second: “because she’d heard the anecdotes about underground use, including a cocktail known in street slang as the 3V’s: Viread, Viagra and Valium.” Street slang and pill-popping – a revolutionary inspiration for establishing international drug trials and medical policy, to be sure.

    The details of the monkey research is also worth noting. AIDS researchers tried for a long time to study AIDS in chimpanzees, thinking that these primates, our nearest genetic relatives, would be the best subjects to help us unlock the riddles of the paradigm12. But it hasn’t panned out.

    As the Times reported in 2003:

    “In the early days of the [AIDS] epidemic, scientists theorized that the chimp would be a useful model to study the disease in people….only to find that although chimpanzees could contract the AIDS virus, they rarely became sick from it. That distinction makes it hard to use the animals to test treatments or vaccines13.”

    So no chimps in the Center for Disease Control’s (CDC) PrEP studies. Instead, they’re using smaller monkeys called macaques. And doing so, they claim that Tenofovir will protect healthy heterosexuals from contracting a deadly STD. How have they accomplished this remarkable feat? By shoving some proteins up….well, you’ll see.

    Here’s the title of the study: “Prevention of Rectal SHIV Transmission in Macaques by Tenofovir/FTC Combination14”. Here it is again, in greater detail: “Tenofovir/FTC combination protected all 6 treated animals from infection after fourteen repeated rectal SHIV exposures15.”

    As a result, we now know that drugging six monkeys with DNA-chain terminators prevents them from testing positive, by some standard, for up to fourteen anal exposures of “SHIV.” Gosh, I hope we at least bought them dinner.

    But what’s “SHIV”? The paper explains that SHIV stands for “Simian [monkey] Human Immunodeficiency Virus.” But it’s not just any old SHIV: “All animals were subjected to weekly rectal exposures with a low dose of SHIVSF162p3…”

    And what is “SHIVSF162p3”, you ask? Well, who knows? It’s a molecular biology experiment. A laboratory construction of synthetic proteins and genetic material derived from bits and pieces of various monkeys and humans. So, you can see how this relates to heterosexual intercourse in young, healthy men and women in India, Botswana, Thailand and Brazil. Or to sex between healthy gay men [and other non-monkeys].

    But there’s another problem. These studies are being done with “Tenofovir/FTC.” That’s two drugs, not one. Two different drugs, because Tenofovir, on its own, didn’t do what the monkey-rumpers wanted it to. So what’s the point of giving Tenofovir to thousands of healthy individuals?

    But even asking these questions can be dangerous. Criticism of AIDS research has typically been met with a forceful response. Asking questions like those posed above is called “denialism.” A heavy charge like this tends to silence critics. But if, despite this warning, you still don’t think Tenofovir PrEP is a good idea, it probably means one thing: you’re not an AIDS specialist.

    The Times asked Dr. Marcus Conant, a San Francisco AIDS clinician about the drug. His response? Conant “has high hopes that tenofovir PrEP will work wonders. Indeed, he already prescribes it to a half-dozen select patients.”

  4. Mainstream understanding of AIDS is not grounded in reality, but is based on a “model” that is ever-changing. Now it is argued that an “activated” immune system somehow causes AIDS!

    “Prevailing views concerning the pathogenic mechanisms of AIDS have shifted from models that focus primarily on direct HIV-mediated killing of CD4+ T cells to models that emphasize the pathogenic role of generalized immune system activation.”

    But AIDS is poverty, drug abuse, and an endless list of illnesses with many many causes, and many treatments. It is not a one-size-fits-all death sentence…

  5. Following is from an official U.S. government web site of the National Institutes of Health titled ‘Dietary Supplements Fact Sheet: Selenium’ at The good and relevant portions have been placed in boldface (most of what is there) with the bullshit portions underlined (for instance note that HIV is ALWAYS underlined).

    Selenium and HIV
    HIV/AIDS malabsorption can deplete levels of many nutrients, including selenium. Selenium deficiency is associated with decreased immune cell counts, increased disease progression, and high risk of death in the HIV/AIDS population [56,57]. HIV/AIDS gradually destroys the immune system, and oxidative stress may contribute to further damage of immune cells. Antioxidant nutrients such as selenium help protect cells from oxidative stress, thus potentially slowing progression of the disease [58]. Selenium also may be needed for the replication of the HIV virus, which could further deplete levels of selenium [59].

    An examination of 125 HIV-positive men and women linked selenium deficiency with a higher rate of death from HIV [60]. In a small study of 24 children with HIV who were observed for five years, those with low selenium levels died at a younger age, which may indicate faster disease progression [61]. Results of research studies have led experts to suggest that selenium status may be a significant predictor of survival for those infected with HIV [62].

    Researchers continue to investigate the relationship between selenium and HIV/AIDS, including the effect of selenium levels on disease progression and mortality. There is insufficient evidence to routinely recommend selenium supplements for individuals with HIV/AIDS, but physicians may prescribe such supplements as part of an overall treatment plan. It is also important for HIV-positive individuals to consume recommended amounts of selenium in their diet.

    56. Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Spengler U, Sauerbruch T. Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Biol Trace Elem Res 1997;56(1):31-41.

    57. Singhal N and Austin J. A clinical review of micronutrients in HIV infection. J Int Assoc Physicians AIDS Care 2002;1:63-75.

    58. Romero-Alvira D and Roche E. The keys of oxidative stress in acquired immune deficiency syndrome apoptosis. Medical Hypotheses 1998;51(2):169-73.

    59. Patrick L. Nutrients and HIV; Part One – Beta carotene and selenium. Altern Med Rev 1999;4:403-13. [PubMed abstract]

    60. Baum MK, Shor-Posner G, Lai S, Zhang G, Lai H, Fletcher MA, Sauberlich H, Page JB. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:370-4. [PubMed abstract]

    61. Campa A, Shor-Posner G, Indacoche F, Zhang G, Lai H, Asthana D, Scott GB, Baum MK. Mortality risk in selenium-deficient HIV-positive children. J Acquir Immune Defic Syndr Hum Retrovirol 1999;15:508-13. [PubMed abstract]

    62. Baum MK and Shor-Posner G. Micronutrient status in relationship to mortality in HIV-1 disease. Nutr Rev 1998;56:S135-9. [PubMed abstract]

Leave a Reply

Your email address will not be published. Required fields are marked *